Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates ...

Ozempic was originally approved to treat people with Type 2 diabetes, but demand has surged because of the drug’s weight-loss ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

Achieving and maintaining a healthy weight is beneficial for a number of reasons. A healthy weight lowers a person's chance ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.